Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

N-acetylation phenotype in bladder cancer

K W Woodhouse, P C Adams, A Clothier

    Human Toxicology
    |October 1, 1982
    PubMed
    Summary

    The N-acetylation phenotype, a metabolic trait, was studied in bladder cancer patients and controls. Results indicate this phenotype is unlikely to be a major factor in bladder cancer development.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Modification and validation of the Bluebelle Wound Healing Questionnaire (WHQ) for assessing surgical site infection in wounds healing by secondary intention.

    Journal of tissue viability·2025
    Same author

    Interdose control of beta-blockade and arterial blood pressure during chronic oral labetalol treatment.

    British journal of clinical pharmacology·2015
    Same author

    A comparative study of methyldopa and labetalol in the treatment of hypertension.

    British journal of clinical pharmacology·2015
    Same author

    Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.

    British journal of clinical pharmacology·2015
    Same author

    A multicentre open trial of labetalol in New Zealand.

    British journal of clinical pharmacology·2015
    Same author

    Spontaneous reporting of fatal adverse drug reactions.

    The International journal of risk & safety in medicine·2013

    Area of Science:

    • Pharmacogenetics
    • Oncology
    • Metabolism

    Background:

    • The N-acetylation phenotype influences drug metabolism and can be associated with various diseases.
    • Slow acetylators may have altered susceptibility to certain conditions.
    • Understanding genetic factors in bladder cancer pathogenesis is crucial.

    Purpose of the Study:

    • To investigate the association between N-acetylation phenotype and bladder cancer.
    • To determine if slow N-acetylation is a risk factor for bladder cancer development.

    Main Methods:

    • Examined N-acetylation phenotype in 30 bladder cancer patients and 27 controls.
    • Assessed the prevalence of 'slow' and 'fast' acetylator phenotypes.
    • Measured isoniazid half-life within different phenotypes.

    Main Results:

    • 70% of bladder cancer patients and 59% of controls were slow acetylators.
    • The difference in slow acetylator prevalence between groups was not statistically significant (P > 0.30).
    • Isoniazid half-life was comparable between controls and bladder cancer patients across phenotypes.

    Conclusions:

    • The N-acetylation phenotype does not appear to be a significant determinant in the pathogenesis of bladder cancer.
    • Further research may explore other genetic or environmental factors in bladder cancer etiology.

    Related Experiment Videos